Pregabalin Market Size (2024 - 2029)

Pregabalin Market Analysis

The Pregabalin Market is expected to register a CAGR of 5% during the forecast period.

The high and growing prevalence of epilepsy and related disorders, such as neuropathic pain and anxiety disorders, are expected to be primary growth factors for the pregabalin market. Pregabalin is used in the management and treatment of these disorders. For instance, according to the February 2022 update of the World Health Organization, epilepsy was diagnosed in about 50 million people worldwide, with 80% of this population residing in low- and middle-income countries. Further, as per the same source, about 5 million cases of epilepsy were diagnosed yearly. As per estimates, up to 70% of people living with epilepsy could avoid seizures with the right diagnosis and care. Thus, with the increasing awareness about the disease, the demand for effective treatment is expected to increase, fueling market growth.

The rising geriatric population with neuropathic pain is expected to fuel growth in the pregabalin market further as pregabalin is used in neuropathic pain treatment. As the geriatric population increases around the world, the burden of neuropathic pain is further expected to increase over the forecast period. For instance, according to the United Nations Department of Economic and Social Affairs 2022, 771 million people were 65 years or over globally in 2022, and the elderly population is projected to reach 994 million by 2030 and 1.6 billion by 2050. As the elderly population is highly prone to complications such as painful diabetic neuropathy and post-herpetic neuralgia, the rising elderly population is anticipated to propel market growth.

The introduction of new products to the market is anticipated to drive further growth in the industry during the forecast period. For example, in May 2022, Lupin Pharmaceuticals received approval from the FDA for its ANDA for pregabalin capsules in a range of dosages (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg). Therefore, the launch of generic pregabalin is anticipated to drive market growth due to cost-effectiveness and increased availability.

Hence, due to the abovementioned factors, the pregabalin market is expected to grow during the forecast period. However, the availability of alternative treatments, adverse effects associated with pregabalin, and stringent regulatory policies are expected to restrain the pregabalin market during the forecast period.

Pregabalin Industry Segmentation

As per the scope of the report, pregabalin is an anti-convulsive drug used to treat epilepsy, fibromyalgia, neuropathic pain, and other related disorders. It acts by reducing nervous activity and reduces pain. The pregabalin market is segmented by product, application, and geography. By products, the market is segmented as capsules, oral solutions, and other products. By application, the market is segmented as epilepsy, neuropathic pain, anxiety disorder, and other applications. By geography, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. The report offers the value (USD) for the above segments.